WASHINGTON — After getting burned by the high-profile implosion of a digital health company, a senior official at Oklahoma’s Medicaid program said the state would be hesitant to buy into similar products again.
“I don’t want to say we’re not receptive,” Terry Cothran, the senior pharmacy director at Oklahoma Health Care Authority said at the Digital Therapeutics Alliance’s summit this week. “We’re just very, very cautious. It would be hard for me to convince my leadership to take that leap again so soon.”
In 2022, Oklahoma announced it had entered into a value-based agreement to offer Pear Therapeutics’ app-based treatments for substance use disorder and opioid use disorder to Medicaid enrollees. Cothran explained that under the deal, Oklahoma made an upfront payment for the products, called reSET and reSET-O, and would “measure hospital and ER visits on the back end” with the understanding that Pear would reimburse the state if the products didn’t save money.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect